SupraQ-PW an innovative non-invasive ultrasound device for cardiac output and fluid status management for all hospitalised patients.

Deltex Medical已被授予Innovate UK Smart Award，以完成SupraQ-PW的开发。SupraQ-PW是一种创新的手持式无创器械，用于评估所有住院患者的心脏功能和液体状态。临床医生目前缺乏一种简单、可靠、无创的血液动力学监测仪，可以快速准确地评估非通气患者的循环状态，然后指导他们的治疗。SupraQ-PW将用于A&E、术前筛查、重症监护、产科和心脏病学。在新冠肺炎患者的循环系统问题变得严重之前，及时诊断至关重要。用于指导治疗将改善患者的治疗效果，减少住院时间，提高紧张资源的利用率，并带来经济效益。SupraQ-PW将脉冲波超声，其优点是可以回声定位测量点。该系统是非侵入性的，可用于所有医院环境中的非通气清醒患者。这一发展是对无创多普勒超声心输出量设备的最佳设计进行了10多年研究的结果。将探头放置在胸骨上切迹（颈部底部胸骨顶部的V形切迹）中。从这个位置，超声可以被引导到患者的主动脉，而不会有骨骼遮挡波束。这种创新的设备易于使用，并提供准确和可重复的心脏功能和液体状态的测量，而不会对患者造成伤害。SupraQ-PW与Deltex最新的便携式TrueVue监护仪兼容，因此无需额外的监护设备。随着人口老龄化，当今医学面临着越来越复杂的病例。通过改善监测，保护患者免受血液动力学错误的影响，将挽救数千人的生命，改善结果并降低成本。血流动力学不稳定和低血压很常见，会导致心肌梗塞、中风和肾损伤等后果。并发症具有严重的临床和经济后果;计划外重症监护入院;住院时间更长;再入院增加; 30天死亡率增加;出院后患者寿命缩短。在入院时和整个护理过程中快速简单地筛查住院患者的能力将对患者安全、住院护理和出院后结果做出重大贡献。这一发展是Deltex在其使命中的一个重要时刻，为所有住院患者提供无创心输出量测量。SupraQ-PW解决了Deltex直接进入的市场需求，该市场包括4个直接地区和23个分销商，每年可能有1600万台设备。Deltex预计，到推出后的第5年年底，累计销售额将达到3200万英镑。

Deltex Medical has been awarded an Innovate UK Smart Award to complete the development of SupraQ-PW. SupraQ-PW is an innovative hand-held non-invasive device for the assessment of cardiac function and fluid status for all hospitalised patients. Clinicians currently lack a simple, reliable, non-invasive haemodynamic monitor that rapidly and accurately assesses the circulatory status of sick non-ventilated patients, and then guides their treatment. SupraQ-PW will be used in A&E, pre-surgical screening, critical care, obstetrics and cardiology. Prompt diagnosis for Covid-19 patients, is critical before their circulatory problem becomes severe. Use to guide treatment would improve patient outcomes, reduce hospital stay, improve utilization of stretched resources and deliver economic benefits. SupraQ-PW will Pulse Wave ultrasound which has the advantage that it can echolocate the point of measurement. The system is non-invasive and can be used on non-ventilated awake patients across all hospital settings. This development is the result of over 10years research into the optimal design for a non-invasive Doppler ultrasound cardiac output device. The probe is placed in the suprasternal notch (V-shaped notch at top of the sternum at the base of the neck). From this position ultrasound can be directed down the patient's aorta without skeletal bone obscuring the beam. This innovative device is easy to use and provides accurate and reproducible measurements of cardiac function and fluid status without patient harm. SupraQ-PW is compatible with Deltex's latest portable TrueVue monitors such that no additional monitoring device is required.Medicine today faces increasingly complex cases as the population ages. Protecting patients from haemodynamic errors through improved monitoring would save thousands of lives, improve outcomes and reduce costs. Haemodynamic instability and low blood pressure are frequent, with consequences such as myocardial infarctions, stroke and kidney injury. Complications have serious clinical and financial consequences; unplanned intensive care admissions; longer hospital stay; increased readmissions; increased 30-day mortality; and shorter patient lifespan after discharge. The ability to quickly and simply screen in-patients at admission and throughout their care will be a significant contribution to patient safety, in-hospital care and post discharge outcomes. This development is a significant moment for Deltex in its mission to provide non-invasive measurements of cardiac output for all hospitalised patients. SupraQ-PW addresses a market need in Deltex's immediately accessible market of 4 direct territories and 23 distributors and potentially 16 million devices per annum. Deltex expects cumulative sales of £32 million by the end of the 5th year after launch.